

Neal D Shore, Facs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/367078/neal-d-shore-facs-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

14,634
citations

38
h-index

120
g-index

137
ext. papers

18,171
ext. citations

7.9
avg, IF

6.12
L-index

#	Paper	IF	Citations
130	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022 , 1-5	1	0
129	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022 , 18, 35-45	3.6	0
128	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. <i>Journal of Urology</i> , 2022 , 207, 61-69	2.5	0
127	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200193	2.2	5
126	Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.. <i>Current Opinion in Urology</i> , 2022 , 32, 283-291	2.8	0
125	Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 199-207	3.3	3
124	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 832	2.5	0
123	Epidemiology and O-Serotypes of Extraintestinal Pathogenic Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2021 , 205, 826-832	2.5	0
122	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8
121	Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia. <i>Journal of Health Economics and Outcomes Research</i> , 2021 , 8, 42-50	1.6	2
120	Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 367.e7-367.e17	2.8	0
119	Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 52-62	2.8	7
118	Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 578-590	4.2	6
117	New treatments for patients with non-metastatic castration-resistant prostate cancer: A nursing perspective. <i>International Journal of Urological Nursing</i> , 2021 , 15, 47	0.8	0
116	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 647-661	6.2	2
115	Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 323-334	6.2	5
114	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021 , 17, 3137-3150	3.6	8

113	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021 , 4, 543-552	6.7	5
112	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021 , 17, 2907-2921	3.6	5
111	Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 298-307	2.5	5
110	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. <i>European Journal of Cancer</i> , 2021 , 154, 138-146	7.5	3
109	Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 467.e1-467.e11	3.3	1
108	A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 683.e1-683.e10	2.8	2
107	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 680-688	6.2	9
106	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2197-2206	59.2	114
105	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2187-2196	59.2	109
104	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020 , 126, 2935-2937	6.4	
103	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <i>Future Oncology</i> , 2020 , 16, 507-516	3.6	25
102	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , 2020 , 80, 527-544	4.2	18
101	Development and evaluation of the MiCheck test for aggressive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 683.e11-683.e18	2.8	3
100	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 517-526	6.2	48
99	Prospective evaluation of fexapotide trifluate injection treatment of Grade Group 1 prostate cancer: 4-year results. <i>World Journal of Urology</i> , 2020 , 38, 3101-3111	4	
98	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
97	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2091-2102	59.2	550
96	Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 229-229	2.2	2

95	Current and Future Management of Locally Advanced and Metastatic Prostate Cancer. <i>Reviews in Urology</i> , 2020 , 22, 110-123	1	4
94	Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen@ Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. <i>N Engl J Med</i> 2020;382:2187-96. <i>European Urology</i> , 2020 , 78, e196-e197	10.2	2
93	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. <i>European Urology</i> , 2020 , 78, 847-853	10.2	2
92	Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. <i>Prostate</i> , 2020 , 80, 1159-1176	4.2	7
91	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2345-2357	59.2	143
90	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020 , 383, 1040-1049	59.2	96
89	A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. <i>World Journal of Urology</i> , 2020 , 38, 111-119	4	2
88	A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. <i>Pharmacoeconomics - Open</i> , 2020 , 4, 439-447	2.1	5
87	Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 416-422	3.3	6
86	Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. <i>Targeted Oncology</i> , 2019 , 14, 527-539	5	35
85	Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States. <i>Urology</i> , 2019 , 130, 72-78	1.6	4
84	A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 412-425	3.5	4
83	Efficacy and safety of fexapotide trifluate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287218820807	3.2	3
82	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 75, 285-293	10.2	83
81	Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAACT). <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 457-463.e6	3.3	16
80	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2974-2986	2.2	285
79	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 4172-4180	6.4	34
78	Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5000-5000 ^{2,2} 13		

77	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5076-5076	2.2	7
76	A Clinician@ Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). <i>Journal of Urology</i> , 2019 , 201, 682-692	2.5	38
75	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1235-1246	59.2	380
74	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019 , 2, 265-273	6.7	44
73	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2018 , 200, 344-352	2.5	37
72	Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. <i>World Journal of Urology</i> , 2018 , 36, 801-809	4	8
71	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. <i>Medical Oncology</i> , 2018 , 35, 56	3.7	4
70	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. <i>European Urology Focus</i> , 2018 , 4, 547-553	5.1	21
69	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
68	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5225-5232	12.9	12
67	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018 , 23, 193-202	5.7	51
66	eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 149-154	3.3	22
65	Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. <i>Urology</i> , 2018 , 115, 39-44	1.6	51
64	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
63	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2465-2474	59.2	525
62	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 71, 656-664	10.2	44
61	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 945-952	4	40
60	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 2451-2459	12.9	48

59	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 72, 10-13	10.2	19
58	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017 , 104, 150-159	1.6	18
57	Intravesical rAd-IFN γ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3410-3416	2.2	86
56	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017 , 109, 6-18	1.6	12
55	Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. <i>BJU International</i> , 2017 , 119, 239-244	5.6	12
54	Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 190-190	2.2	7
53	Alternative payment models. <i>Reviews in Urology</i> , 2017 , 19, 198-199	1	5
52	Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. <i>Canadian Journal of Urology</i> , 2017 , 24, 8802-8813	0.8	101
51	Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. <i>Journal of Urology</i> , 2016 , 195, 612-8	2.5	45
50	An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2016 , 11, 153-159	0.4	
49	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 153-163	21.7	164
48	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 438-44	10.2	25
47	Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2016 , 195, 1529-1538	2.5	107
46	Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16546-e16546	2.2	4
45	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016 , 70, 963-970	10.2	78
44	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016 , 96, 116-120	1.6	8
43	A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2015 , 10, 186-192	0.4	8
42	A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3862-9	12.9	62

41	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>European Journal of Cancer</i> , 2015 , 51, 1812-21	7.5	84
40	Advances in the understanding of cancer immunotherapy. <i>BJU International</i> , 2015 , 116, 321-9	5.6	20
39	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , 2015 , 68, 570-7	10.2	41
38	Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study. <i>Urology Practice</i> , 2015 , 2, 26-32	0.8	13
37	Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective. <i>Urology</i> , 2015 , 85, 717-24	1.6	37
36	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2015 , 16, 152-60	21.7	856
35	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 187-187	2.2	5
34	Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. <i>Canadian Journal of Urology</i> , 2015 , 22, 8048-55	0.8	7
33	Challenges and recommendations for early identification of metastatic disease in prostate cancer. <i>Urology</i> , 2014 , 83, 664-9	1.6	70
32	Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer. <i>Urology Practice</i> , 2014 , 1, 2-6	0.8	
31	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , 2014 , 66, 815-25	10.2	186
30	Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. <i>Urology</i> , 2014 , 83, 1122-8	1.6	41
29	A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5023-5023	2.2	4
28	ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5026-5026	2.2	2
27	Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5029-5029	2.2	1
26	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5051-5051	2.2	2
25	Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5086-5086	2.2	7
24	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9501-9501	2.2	2

23	PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5094-TPS5094	2.2	5
22	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 21-21	2.2	2
21	Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 27-27	2.2	1
20	ODM-201 and the CNS: A clinical perspective.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 275-275	2.2	3
19	A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 83-83	2.2	6
18	A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5041-5041	2.2	
17	Using a combination of plasma and urine biomarkers along with serum PSA in predicting prostate cancer and screening for high-risk cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16026-e16026	2.2	
16	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5040-5040	2.2	
15	Using a combination of urine and plasma biomarkers for the development of a scoring system that can diagnose and predict prognosis of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 163-163	2.2	
14	The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. <i>Journal of Urology</i> , 2013 , 190, 2161-7	2.5	125
13	Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3800-6	2.2	145
12	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , 2013 , 14, 1193-9	21.7	123
11	A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer. <i>Hospital Practice (1995)</i> , 2013 , 41, 78-80	2.2	1
10	Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. <i>Cancer Control</i> , 2013 , 20, 7-16	2.2	17
9	Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 1187-97	59.2	3075
8	Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. <i>BJU International</i> , 2012 , 109, 226-32	5.6	19
7	LHRH Agonists for the Treatment of Prostate Cancer: 2012. <i>Reviews in Urology</i> , 2012 , 14, 1-12	1	33
6	Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 1-24	0.6	

5	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. <i>Lancet, The</i> , 2011 , 377, 813-22	4 ⁰	1443
4	The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2011 , 2, 377-83	4.9	23
3	NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 305-10	5.9	29
2	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 411-22	59.2	3838
1	Free autogenous muscle transplantation in rabbits: a technique for correction of urinary incontinence. <i>Journal of Urology</i> , 1985 , 134, 1047-9	2.5	1